Overview

Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This study assessed the safety, tolerability, and efficacy of LCZ696 in severe hypertensive Japanese patients
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696
Sacubitril and valsartan sodium hydrate drug combination